Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 77Multiple Myeloma 40Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma 37Lymphoma, Non-Hodgkin 27Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 18Burkitt Lymphoma 18Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 17Neoplasms, Plasma Cell 16Lymphoma, B-Cell 16Leukemia, Myeloid, Acute 16Neuroblastoma 12Hodgkin Disease 12Lymphoma, Large-Cell, Immunoblastic 11Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 9Lymphoma, B-Cell, Marginal Zone 9Inflammatory Breast Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Ovarian Neoplasms 8Immunoblastic Lymphadenopathy 7Neoplasm Metastasis 6Melanoma 6Leukemia, Myeloid, Chronic-Phase 6Hematologic Neoplasms 6

Interventions

Thrombopoietin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Jacobs syndrome × Cyclophosphamide × Clear all
NCT02572596 2017-02-09

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Beijing Chao Yang Hospital

Phase NA Unknown
200 enrolled
Plasma cell

Jacobs syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡